The weight loss industry is once again under scrutiny as regulators issue a joint warning about the improper promotion of medicines for weight management. The Medicines and Healthcare products Regulatory Agency (MHRA), Advertising Standards Authority (ASA), and General Pharmaceutical Council (GPhC) have come together to highlight concerns over businesses advertising products that are either still undergoing regulatory review or classified as prescription-only medicines (POMs). This is a crucial reminder of the strict rules surrounding the marketing of medicinal products in the UK, designed to protect patients from potentially misleading or even dangerous claims.
The warning specifically targets instances where businesses advertise 'pipeline products', such as newer forms of oral and injectable weight management treatments, which are still awaiting regulatory approval. This includes promoting newly licensed oral GLP-1s, which can only be prescribed by a healthcare professional. Advertisements creating waiting lists for these products or using generic terms like 'GLP-1 tablets' to refer to POMs are also deemed non-compliant with the CAP Code.
Julian Beach, MHRA Executive Director of Healthcare Quality and Access, stresses that medicinal products cannot be treated as ordinary consumer goods. "Improper use can lead to serious health consequences," he warns. Creating consumer demand for a product before it has received UK regulatory appraisal is not permitted, and advertising POMs to the public is strictly prohibited under the Human Medicines Regulations.
The regulators are urging advertisers in the weight management sector to review their practices urgently and ensure compliance with the rules. Jess Tye, Regulatory Projects Manager at the ASA, notes that the fast-moving nature of this sector requires swift action against non-compliant advertisers. Roz Gittins, Chief Pharmacy Officer at the GPhC, reiterates that enforcement action will be taken against pharmacies and registrants who fail to meet professional standards.
This joint warning serves as a timely reminder of the importance of protecting patients and upholding professional standards within the healthcare sector. The regulators advise that consulting with a healthcare professional remains the most effective way for individuals to determine suitable treatment options, ensuring medical decisions are based on individual patient needs rather than potentially misleading advertising claims.
For UK patients, this means being cautious of any advertising promoting specific prescription-only weight management drugs or those not yet licensed for use in the UK. It is essential to be aware that only medicines licensed and approved by the MHRA can be safely advertised and used in the UK market.
The regulators are committed to acting swiftly against non-compliant advertisers, ensuring that patients are protected from potentially misleading claims and promoting a safe and responsible healthcare sector.